BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 32580068)

  • 41. In silico analysis of long non-coding RNAs in medulloblastoma and its subgroups.
    Joshi P; Jallo G; Perera RJ
    Neurobiol Dis; 2020 Jul; 141():104873. PubMed ID: 32320737
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Subgroup and subtype-specific outcomes in adult medulloblastoma.
    Coltin H; Sundaresan L; Smith KS; Skowron P; Massimi L; Eberhart CG; Schreck KC; Gupta N; Weiss WA; Tirapelli D; Carlotti C; Li KKW; Ryzhova M; Golanov A; Zheludkova O; Absalyamova O; Okonechnikov K; Stichel D; von Deimling A; Giannini C; Raskin S; Van Meir EG; Chan JA; Fults D; Chambless LB; Kim SK; Vasiljevic A; Faure-Conter C; Vibhakar R; Jung S; Leary S; Mora J; McLendon RE; Pollack IF; Hauser P; Grajkowska WA; Rubin JB; van Veelen MC; French PJ; Kros JM; Liau LM; Pfister SM; Kool M; Kijima N; Taylor MD; Packer RJ; Northcott PA; Korshunov A; Ramaswamy V
    Acta Neuropathol; 2021 Nov; 142(5):859-871. PubMed ID: 34409497
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A simplified approach using Taqman low-density array for medulloblastoma subgrouping.
    Cruzeiro GAV; Salomão KB; de Biagi CAO; Baumgartner M; Sturm D; Lira RCP; de Almeida Magalhães T; Baroni Milan M; da Silva Silveira V; Saggioro FP; de Oliveira RS; Dos Santos Klinger PH; Seidinger AL; Yunes JA; de Paula Queiroz RG; Oba-Shinjo SM; Scrideli CA; Nagahashi SMK; Tone LG; Valera ET
    Acta Neuropathol Commun; 2019 Mar; 7(1):33. PubMed ID: 30832734
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A preliminary study on the mechanism of VASH2 in childhood medulloblastoma.
    Liu W; Fu Y; Wang M; Zhao J; Chen J; Wang Y; Qin H
    Sci Rep; 2023 Oct; 13(1):17153. PubMed ID: 37821528
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Medulloblastoma: Molecular understanding, treatment evolution, and new developments.
    Liu X; Ding C; Tan W; Zhang A
    Pharmacol Ther; 2020 Jun; 210():107516. PubMed ID: 32105673
    [TBL] [Abstract][Full Text] [Related]  

  • 46. M1 macrophage recruitment correlates with worse outcome in SHH Medulloblastomas.
    Lee C; Lee J; Choi SA; Kim SK; Wang KC; Park SH; Kim SH; Lee JY; Phi JH
    BMC Cancer; 2018 May; 18(1):535. PubMed ID: 29739450
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Neogenin1 is a Sonic Hedgehog target in medulloblastoma and is necessary for cell cycle progression.
    Milla LA; Arros A; Espinoza N; Remke M; Kool M; Taylor MD; Pfister SM; Wainwright BJ; Palma V
    Int J Cancer; 2014 Jan; 134(1):21-31. PubMed ID: 23775842
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Downregulation of ARID1B, a tumor suppressor in the WNT subgroup medulloblastoma, activates multiple oncogenic signaling pathways.
    Deogharkar A; Singh SV; Bharambe HS; Paul R; Moiyadi A; Goel A; Shetty P; Sridhar E; Gupta T; Jalali R; Goel N; Gadewal N; Muthukumar S; Shirsat NV
    Hum Mol Genet; 2021 Aug; 30(18):1721-1733. PubMed ID: 33949667
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Signaling pathway and molecular subgroups of medulloblastoma.
    Li KK; Lau KM; Ng HK
    Int J Clin Exp Pathol; 2013; 6(7):1211-22. PubMed ID: 23826403
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Exosomal microRNAs induce tumor-associated macrophages via PPARγ during tumor progression in SHH medulloblastoma.
    Zhu L; Yang Y; Li H; Xu L; You H; Liu Y; Liu Z; Liu X; Zheng D; Bie J; Li J; Song C; Yang B; Luo J; Chang Q
    Cancer Lett; 2022 Jun; 535():215630. PubMed ID: 35304257
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immunohistochemical Surrogates for Molecular Stratification in Medulloblastoma.
    Chinnam D; Saraswati A; Jogunoori S; Verma A; Kiran T; Salunke P; Gupta N; Kumar N; Madan R; Radotra BD; Gupta K
    Appl Immunohistochem Mol Morphol; 2023 Sep; 31(8):561-568. PubMed ID: 37471625
    [TBL] [Abstract][Full Text] [Related]  

  • 52. DNA methylation profiling is a method of choice for molecular verification of pediatric WNT-activated medulloblastomas.
    Korshunov A; Sahm F; Zheludkova O; Golanov A; Stichel D; Schrimpf D; Ryzhova M; Potapov A; Habel A; Meyer J; Lichter P; Jones DTW; von Deimling A; Pfister SM; Kool M
    Neuro Oncol; 2019 Feb; 21(2):214-221. PubMed ID: 30252101
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study.
    Schwalbe EC; Lindsey JC; Nakjang S; Crosier S; Smith AJ; Hicks D; Rafiee G; Hill RM; Iliasova A; Stone T; Pizer B; Michalski A; Joshi A; Wharton SB; Jacques TS; Bailey S; Williamson D; Clifford SC
    Lancet Oncol; 2017 Jul; 18(7):958-971. PubMed ID: 28545823
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mir-449a, a potential diagnostic biomarker for WNT group of medulloblastoma.
    Li Y; Jiang T; Shao L; Liu Y; Zheng C; Zhong Y; Zhang J; Chang Q
    J Neurooncol; 2016 Sep; 129(3):423-431. PubMed ID: 27406588
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Medulloblastoma: clinicopathological parameters, risk stratification, and survival analysis of immunohistochemically validated molecular subgroups.
    Eid AM; Heabah NAE
    J Egypt Natl Canc Inst; 2021 Feb; 33(1):6. PubMed ID: 33555447
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Risk stratification of childhood medulloblastoma in the molecular era: the current consensus.
    Ramaswamy V; Remke M; Bouffet E; Bailey S; Clifford SC; Doz F; Kool M; Dufour C; Vassal G; Milde T; Witt O; von Hoff K; Pietsch T; Northcott PA; Gajjar A; Robinson GW; Padovani L; André N; Massimino M; Pizer B; Packer R; Rutkowski S; Pfister SM; Taylor MD; Pomeroy SL
    Acta Neuropathol; 2016 Jun; 131(6):821-31. PubMed ID: 27040285
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Elevated Kir2.1/nuclear N2ICD defines a highly malignant subtype of non-WNT/SHH medulloblastomas.
    Wang YX; Wu H; Ren Y; Lv S; Ji C; Xiang D; Zhang M; Lu H; Fu W; Liu Q; Yan Z; Ma Q; Miao J; Cai R; Lan X; Wu B; Wang W; Liu Y; Wang DZ; Cao M; He Z; Shi Y; Ping Y; Yao X; Zhang X; Zhang P; Wang JM; Wang Y; Cui Y; Bian XW
    Signal Transduct Target Ther; 2022 Mar; 7(1):72. PubMed ID: 35273141
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Medulloblastoma with transitional features between Group 3 and Group 4 is associated with good prognosis.
    Łastowska M; Trubicka J; Niemira M; Paczkowska-Abdulsalam M; Karkucińska-Więckowska A; Kaleta M; Drogosiewicz M; Perek-Polnik M; Krętowski A; Cukrowska B; Grajkowska W; Dembowska-Bagińska B; Matyja E
    J Neurooncol; 2018 Jun; 138(2):231-240. PubMed ID: 29427151
    [TBL] [Abstract][Full Text] [Related]  

  • 59. RBM5 Acts as Tumor Suppressor in Medulloblastoma through Regulating Wnt/β-Catenin Signaling.
    Yu J; Ji G; Shi W; Zhao R; Shen W; Zheng J; Li H; Jiang F
    Eur Neurol; 2020; 83(3):242-250. PubMed ID: 32610314
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Paired box gene 8 (PAX8) expression is associated with sonic hedgehog (SHH)/wingless int (WNT) subtypes, desmoplastic histology and patient survival in human medulloblastomas.
    Harter PN; Baumgarten P; Zinke J; Schilling K; Baader S; Hartmetz AK; Schittenhelm J; Beschorner R; Liebner S; Schulte D; Plate KH; Gutwein P; Korshunov A; Pfister SM; Jones DT; Doberstein K; Mittelbronn M
    Neuropathol Appl Neurobiol; 2015 Feb; 41(2):165-79. PubMed ID: 25287489
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.